1. Home
  2. PAAC vs CDXS Comparison

PAAC vs CDXS Comparison

Compare PAAC & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PAAC

Proem Acquisition Corp I Ordinary Shares

N/A

Current Price

$10.05

Market Cap

179.0M

Sector

N/A

ML Signal

N/A

Logo Codexis Inc.

CDXS

Codexis Inc.

N/A

Current Price

$1.05

Market Cap

154.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
PAAC
CDXS
Founded
2025
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
179.0M
154.4M
IPO Year
2025
2008

Fundamental Metrics

Financial Performance
Metric
PAAC
CDXS
Price
$10.05
$1.05
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $6.14
AVG Volume (30 Days)
51.9K
★ 849.5K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 43.82
EPS
★ N/A
N/A
Revenue
N/A
★ $138,590,000.00
Revenue This Year
N/A
$4.80
Revenue Next Year
N/A
$18.91
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 32.30
52 Week Low
$9.93
$0.90
52 Week High
$10.15
$2.98

Technical Indicators

Market Signals
Indicator
PAAC
CDXS
Relative Strength Index (RSI) 55.92 43.21
Support Level $10.00 $0.93
Resistance Level $10.15 $1.29
Average True Range (ATR) 0.01 0.10
MACD 0.00 0.01
Stochastic Oscillator 59.49 43.75

Price Performance

Historical Comparison
PAAC
CDXS

About PAAC Proem Acquisition Corp I Ordinary Shares

Proem Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

About CDXS Codexis Inc.

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: